RPS6KB1 and tuberous sclerosis: The decreased cerebral blood flow resulting from the blockade of the S6K1 branch of mTOR signaling could potentially offer therapeutic benefits in the treatment of tuberous sclerosis-ASD in humans (Gkogkas et al., 2013; Kelleher & Bear, 2008; Sharma & Mehan, 2021; Winden et al., 2018).